ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Feb 22, 2019||ENDRA Life Sciences to Host Fourth Quarter and Full Year 2018 Results Conference Call on Monday, March 11, 2019 at 4:30 p.m. ET|
|Jan 22, 2019||ENDRA Life Sciences Announces Artificial Intelligence Initiative|
|Jan 02, 2019||ENDRA Life Sciences Issues Shareholder Letter|
|Dec 17, 2018||ENDRA Life Sciences Provides Update on First Human Study|
|Dec 03, 2018||ENDRA Life Sciences to Present at the 11th Annual LD Micro Main Event on December 5, 2018|
|Day Range||1.62 - 1.84|
|52 Week Range||1.44 - 5.75|
|Bid/Ask||1.69 / 1.79|
|Bid/Ask Size||100 X 200|
|Market Cap||13.29 million|
|Shares Outstanding||7.42 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|